Centchroman versus Tamoxifen in the management of Mastalgia: A Randomized Controlled Clinical Trial
Abstract
Introduction and Objective: Mastalgia is defined as painful nodularity for more than 1 week of menstrual cycle.The long list of drugs highlights the ongoing debate about the drug of choice for the management of mastalgia.So in this study, we compared the effectiveness and cost of Centchroman and Tamoxifen in the management ofmastalgia.Materials and methods: A total of 106 female patients with the clinical diagnosis of mastalgia were enrolledin the study and randomized to 1:1 ratio into Centchroman and Tamoxifen group for a period of 1 year. Theduration of therapy was 3 months. All patients completed the study and follow up. The response of therapy wasassessed on 1, 2, 3 and 6 months by using a Visual Analogue Scale (VAS).Results: Baseline mean VAS score was 6.25 in Tamoxifen and 6.49 in Centchroman group.There was markedimprovement in VAS score after the treatment in both the groups, which was statistically significant withgreater reduction in Centchroman group(p= 0.001).The number of patients who achieved VAS less than 3 were51(96.2%) in Centchroman and 49(92.5%) in Tamoxifen group at the end of treatment. Tamoxifen was found tobe statistically significant and cost-effective (p <0.001) in comparison to Centchroman.Conclusion: We conclude that Centchroman is not inferior to Tamoxifen and both the drugs effectively reducedpain, however Centchroman reduced the pain more than Tamoxifen.
Published
2016-03-26
How to Cite
KHADKA, S et al.
Centchroman versus Tamoxifen in the management of Mastalgia: A Randomized Controlled Clinical Trial.
J Soc Surg Nep, [S.l.], v. 18, mar. 2016.
ISSN 2392-4772.
Available at: <https://jssn.org.np/index.php?journal=jssn&page=article&op=view&path%5B%5D=151>. Date accessed: 19 apr. 2024.
Section
Abstract
Keywords
Centchroman, Mastalgia, Tamoxifen, VAS
Copyright and Open Access Policy
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
JSSN applies the Creative Commons Attribution (CC BY) license to all works we publish. Under the CC BY license, authors retain ownership of the copyright for their article, but authors allow anyone to download, reuse, reprint, distribute, and/or copy articles in JSSN, so long as the original authors and source are cited. No permission is required from the authors or the publishers.
Article by JSSN is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at http://www.jssn.org.np/index.php?journal=jssn.